Levels of evidence and study designs: A brief introduction to dermato-epidemiologic research methodology

被引:10
作者
Chen, Yen-Ning [1 ,2 ]
Chi, Ching-Chi [2 ,3 ,4 ]
机构
[1] Chang Gung Mem Hosp, Dept Med Educ, Linkou Main Branch, Taoyuan, Taiwan
[2] Chang Gung Univ, Coll Med, Sch Med, Taoyuan, Taiwan
[3] Chang Gung Mem Hosp, Dept Dermatol, Linkou Main Branch, Taoyuan, Taiwan
[4] Chang Gung Mem Hosp, Dept Dermatol, Linkou Main Branch, 5 Fuxing St, Taoyuan 333423, Taiwan
关键词
Evidence pyramid; evidence-based dermatology; evidence-based medicine; level of evidence; study design; LUNG-CANCER; SMOKING; MORTALITY; ASSOCIATION; ENVIRONMENT; EFFICACY; MEDICINE; DISEASE;
D O I
10.4103/ds.DS-D-23-00159
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Levels of evidence (LOE), also known as hierarchies of evidence, are determined primarily by the inherent bias and validity of the study designs. Understanding LOE is a crucial preliminary step in practicing evidence-based medicine (EBM) or evidence-based dermatology. These hierarchies facilitate the efficient acquisition of the best available evidence for clinicians in decision-making, as well as guiding researchers in conducting new studies with appropriate designs while considering the next higher LOE necessary to improve the quality of currently available evidence. This article provides a concise overview of LOE and study designs based on the 2011 Oxford Centre for Evidence-Based Medicine LOE for treatment benefits. We utilize examples from medical literature to elucidate the strengths and limitations of various study designs. Furthermore, we shed light on the key concepts of the updated evidence pyramid and how the EBM research roadmap functions to bridge the gap between current best evidence and clinical practice.
引用
收藏
页码:199 / 205
页数:7
相关论文
共 29 条
[1]   Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial [J].
Blauvelt, Andrew ;
Papp, Kim A. ;
Griffiths, Christopher E. M. ;
Randazzo, Bruce ;
Wasfi, Yasmine ;
Shen, Yaung-Kaung ;
Li, Shu ;
Kimball, Alexa B. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) :405-417
[2]   The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro [J].
Caly, Leon ;
Druce, Julian D. ;
Catton, Mike G. ;
Jans, David A. ;
Wagstaff, Kylie M. .
ANTIVIRAL RESEARCH, 2020, 178
[3]   Risk of Uveitis Among People With Psoriasis A Nationwide Cohort Study [J].
Chi, Ching-Chi ;
Tung, Tao-Hsin ;
Wang, Jui ;
Lin, Yu-Sheng ;
Chen, Yu-Fen ;
Hsu, Tsui-Kan ;
Wang, Shu-Hui .
JAMA OPHTHALMOLOGY, 2017, 135 (05) :415-422
[4]   Evidence-based dermatology [J].
Chi, Ching-Chi .
DERMATOLOGICA SINICA, 2013, 31 (01) :2-6
[5]   Progress in evidence-based medicine: a quarter century on [J].
Djulbegovic, Benjamin ;
Guyatt, Gordon H. .
LANCET, 2017, 390 (10092) :415-423
[6]   MORTALITY IN RELATION TO SMOKING - 40 YEARS OBSERVATIONS ON MALE BRITISH DOCTORS [J].
DOLL, R ;
PETO, R ;
WHEATLEY, K ;
GRAY, R ;
SUTHERLAND, I .
BRITISH MEDICAL JOURNAL, 1994, 309 (6959) :901-911
[7]   MORTALITY IN RELATION TO SMOKING - 10 YEARS OBSERVATIONS OF BRITISH DOCTORS [J].
DOLL, R ;
HILL, AB .
BRITISH MEDICAL JOURNAL, 1964, 1 (539) :1399-&
[8]   MORTALITY IN RELATION TO SMOKING - 20 YEARS OBSERVATIONS ON MALE BRITISH DOCTORS [J].
DOLL, R ;
PETO, R .
BRITISH MEDICAL JOURNAL, 1976, 2 (6051) :1525-1536
[9]   SMOKING AND CARCINOMA OF THE LUNG - PRELIMINARY REPORT [J].
DOLL, R ;
HILL, AB .
BRITISH MEDICAL JOURNAL, 1950, 2 (4682) :739-748
[10]   THE MORTALITY OF DOCTORS IN RELATION TO THEIR SMOKING HABITS - A PRELIMINARY REPORT [J].
DOLL, R ;
HILL, AB .
BMJ-BRITISH MEDICAL JOURNAL, 1954, 1 (4877) :1451-1455